Waxhaw, North Carolina, United States
Passionate executive with 15+ years’ experience leading teams to build and/or extract maximum value from internal/external scientific and clinical opportunities to advance organizational pipeline development and strategic goals. I care about people and prioritize talent development for both my teams and throughout my organization. I have deep subject matter expertise, strategic vision, and outstanding communication and trust building skills that have resulted in tangible successes in each of my roles across industry and academia. I have enjoyed time as an independent investigator and leader across therapeutic areas and organizations (industry / academia / government / non-profits), with extensive international / global experience. As a person, I love soccer (playing, watching, anything) and sports in general, when I travel I prefer to just walk around and explore rather than overly plan (especially in Paris, France where I spent 4 years as a teenager), and I try to surround myself with people who are genuine and respectful of others.
A stealth-mode TechBio company developing life-saving cancer therapies through an unwavering commitment to tech-enabled precision medicine.
Responsible for the partnering strategy to position Caris as the industry leading innovator and strategic partner of choice for all of BioPharma’s molecular oncology and precision medicine drug development needs. Scaled the organization 10x while driving an 8x revenue increase at a 65% CAGR over four years, leading 150+ collaborations across 100+ unique companies to support pan-modality drug development and commercialization. Established three core business lines from the ground up—Diagnostic Services (NGS, Companion Diagnostics, Trial Matching), Data Licensing (Real-World Multi-Modal Data), and Caris Discovery (Novel Target Identification + Out-Licensing).
Weill Cornell Medical College faculty appointment on the Pathway Recognizing Academic Achievement and Scholarship, area of excellence in Investigation.
Responsible for leadership of the Opdivo & Yervoy GU and indoleamine 2,3-dioxygenase (IDO) late development teams, focusing on the maximization of these assets to increase survival and quality of life for patients with bladder cancer, RCC, and prostate cancer.
Development lead and co-chair of BMS/ONO Pharmaceutical Co. immuno-oncology joint development team for collaboration assets including Opdivo, Yervoy and early development compounds in Japan, South Korea, and Taiwan. Portfolio includes 10+ assets, with 100+ company sponsored clinical trials. Lead matrix team and set clinical development strategy for Oncology Clinical Collaborations & Evaluation. Accountable for ~50 trials (including ph1/2 signal seeking and ph3 registrational programs).
Led Oncology S&E team responsible for the identification and evaluation of external clinical stage assets for licensing, clinical collaborations and M&A. Led due diligence teams and supported deal negotiation for major licensing deals (e.g. Nektar), phI-III clinical collaborations (e.g. Clovis, Exelixis, Daiichi) and other research partnerships. Leveraged prior R&D Oncology experience to develop and execute licensing and partnering strategy with oncology leadership.
• Program development – led Research Development office; identified innovative research projects for targeted novel funding streams across therapeutic areas (e.g. cardiovascular, metabolic, inflammation, infectious diseases, oncology, neurology/CNS, pharmacology); led private and public academic partnerships to develop cross-disciplinary programs; increased grant support through program and resource development • Internal/External relations – liaised with internal and external thought leaders, federal and non-federal (foundation) representatives; promoted investigator research portfolios; prepared expert and lay content for public affairs and development offices; interfaced with development, legal, finance, and research administrative offices. • International partnerships – negotiated research cooperative agreements, memorandum of understandings (MOUs), joint research programs, and trainee exchange programs during invited visits to premier academic institutions in Europe and Asia. • Public speaking – provided expertise as invited speaker on research funding, grantsmanship and public speaking at conferences and workshops (SPARC, Tri-Institutional Network, WCMC-Qatar and many others).
• Coordinated Advance Biomedical Sciences (ABS) requirement, identified mentored positions and funding for student research, developed web content for research related resources, organized annual medical student research forum and acted in an advisory role to medical students. • Served on medical education committees, including Junior Faculty Committee Member for the Liaison Committee on Medical Education (LCME) and Education Unit (development of innovative medical education curriculum as part of comprehensive education reform process)